Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a many-sided condition requiring strategic and tailored program design strategies to address the components successfully and comprehensively. Formerly non-alcoholic steatohepatitis (NASH), the new nomenclature represents a shift in our understanding of the disease, serves to reduce stigma, and broadens the potential patient base. However, the multifaceted nature and changing regulatory guidance can create hurdles throughout a clinical trial; in this poster, we address some of these challenges and touch on best practices for a successful MASH study.
Check out our poster, presented at Paris MASH Meeting 2024, for some of the following key takeaways:
- The meaningful role of standardized methodology
- Patient selection criteria optimization
- Mitigation strategies to enhance trial outcomes
